Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. - Wikidata - awgldk - TriplyDB

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

http://www.wikidata.org/entity/Q36937170

about

Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation Targeting the adaptive molecular landscape of castration-resistant prostate cancer Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer Androgen biosynthesis in castration-resistant prostate cancer AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.Constitutive activity of the androgen receptor.Genetic defects in dolichol metabolism.Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.Promiscuity and diversity in 3-ketosteroid reductases.The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).Androgen receptor: structure, role in prostate cancer and drug discovery.Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer.Minireview: Androgen metabolism in castration-resistant prostate cancer.Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.Is the Expression of Androgen Receptor Protein Associated With the Length of AC Repeats in the Type III 5-α Reductase Gene in Prostate Cancer Patients?Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit Mechanisms of androgen receptor activation in castration-resistant prostate cancer Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.5α-reductase type 3 enzyme in benign and malignant prostate.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.Metabolic and toxicological considerations of newly approved prostate cancer drugs.

P2860

Q27007208-5C8ECD17-3685-4956-8F60-5C7A80B5FAC3 Q27022821-182991AE-507E-4BC2-B138-CBB89B85B540 Q27024775-A10AD2D0-5624-4D59-AF56-90B3322344E4 Q27026044-D570020C-AB0D-4014-90B6-D22BAB9C6DD3 Q27853062-3684F1B6-6AC3-42E2-AD8E-33D3F6D64E2B Q33563699-894675B6-FACF-4E4E-96D7-18C63F5E46D2 Q33621403-0C43F4A6-9050-4AD7-8027-986DF25E1272 Q33770742-EA8D30EC-DF0E-4463-ABC7-88D0F6398E3F Q33775717-C8070354-3DA0-4CBA-A957-ADD9FB4A71FF Q34108738-5D2F7A3E-1451-4C7D-ACD7-42A66C2C86E2 Q34294888-36A62454-D88F-46B0-9B43-8406F5F41026 Q34382405-0B68B3F1-1ADC-4F70-8620-E9893F7810BE Q34461177-8917C715-7A54-4166-8286-A9B5E9463C5E Q34775572-372E2E52-DECC-4D44-BB5D-C07B3E1F5531 Q34798492-DB5C0D91-EA22-4D30-9C48-AECB75D7526C Q35102971-CEE13CA5-3400-4CF4-909C-6C994804010D Q35553876-5D39BDDF-E557-4347-8383-775F8912A11B Q35603660-3DF1C9AB-1C4D-4E5C-80B6-9DE6C180D0E8 Q35691232-D917B998-628C-4594-B1F3-C1C40DAE49AC Q35978237-3F8869E5-504C-49CB-B5DE-E3E2EC8B2126 Q36004694-A690A53E-C98F-4A5E-9677-11E2E14ABFE5 Q36055229-300EAB05-7D20-48B5-99CC-5C931B8CC60F Q36063723-A0F04859-C6E2-448F-8E28-37D385993CC7 Q36386969-89ECAF94-261F-4A92-B9AB-56B0F6353619 Q36398998-A8CB4AD7-53F4-4A2E-BB88-FBA8C8144854 Q36440631-9ACC8049-CA23-4E99-B279-870CBA4DC000 Q36789277-8CD22D23-2921-49DB-B16C-869EC184224B Q36799180-CA9DA2B7-3B85-4DD0-B252-25B98D3B37EF Q36937716-19410A93-B2AA-4803-91F8-1CF2E2EFEFD6 Q37076775-9FBA0D11-9232-4445-8D26-38475769ACED Q37139070-FD948EC7-9AE3-44B3-BB5E-E0094C95F593 Q37157965-068F7404-5FB7-4261-978B-3F51E8C61911 Q37537958-F801D76D-AE2E-4729-9833-704A5B64DDD8 Q37620953-FCE0960F-6479-4268-B0B0-0A78F1E2443B Q37628940-4C64BAF3-FBB0-473E-922F-0D9FD148AF6C Q37665657-81639962-128D-43AE-A448-54EE1147A914 Q37709925-26B390F7-A8F8-4643-B123-7B8CFF3830F6 Q37712234-B58F7CD4-4CC5-4539-B5C5-62A0D72F4E27 Q37737611-4DAB5812-6841-4305-98C3-95AD61481BA3 Q38098596-B0E62060-8CCD-4CC1-A586-465266D0B5A5

P2860

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

http://www.wikidata.org/entity/Q36937170

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Distinct patterns of dysregula ...... static prostate cancer tumors.

@en

type

label

Distinct patterns of dysregula ...... static prostate cancer tumors.

@en

prefLabel

Distinct patterns of dysregula ...... static prostate cancer tumors.

@en

P1433

Q36937170-68A6DE7E-3D82-4353-930B-44A9021C817C

P1476

Q36937170-7343572E-9C99-4AF6-9143-2057800A4941

P2093

Q36937170-35B064D1-9D9A-4CD1-846B-334B7D870F76

Q36937170-36BC5C72-07D6-4309-8E54-A634CB4D5C55

Q36937170-4143C898-BDCE-4A5F-9C70-2187325C936F

Q36937170-45EB9F1D-67FB-47B9-8159-4FF422ED3120

Q36937170-5BC644F2-6314-486D-8FFE-00A906C81B2E

Q36937170-6FDD8A2D-BED9-45E0-922F-1C41EB2359D0

Q36937170-AF904D4D-B0E4-472E-AEAA-572DCB688DFE

Q36937170-D8A6449B-A1DD-4FDC-B120-ADFF4EFCFFFC

Q36937170-EF18A5AB-EEAC-411C-8417-DF17439BEB41

P2860

Q36937170-064D93FC-FF74-412E-8F17-16202C4720D2

Q36937170-09FDE8AA-870E-49E6-8669-6A4DC4674983

Q36937170-0BA87782-65C7-4510-A9E0-741B593EE46D

Q36937170-1E870C9D-2C69-4A5B-BC06-C0AE6CA66E65

Q36937170-23362DA2-F1C4-46CF-9477-9EAD8356C1A7

Q36937170-26EEF9EE-40AC-443A-B0E1-0CF21C057AB0

Q36937170-320F2C46-4F75-429C-93CC-18B87FA90CAC

Q36937170-3B1D842B-ECBB-4346-8D6E-74787B6D5278

Q36937170-3FD8CCD8-D5F0-4053-99FE-75A55F7E48DA

Q36937170-4F129AEC-A4DE-432D-AA71-EF1770DC029C

P304

Q36937170-260BFE95-35C5-4A69-95AA-968505FC1A69

P31

Q36937170-99C1943E-CDD1-4094-9CEC-8B4F5A86E073

P356

Q36937170-F9EDB850-70C4-479B-8813-ABCB70D16382

P407

Q36937170-E30C9FA9-D1B7-4595-A4C8-A3C7B1512A0C

P433

Q36937170-74E1BC90-DD03-4E4B-B161-D71F444684AF

P478

Q36937170-E79D9C8C-03BD-45FB-882E-2859CFE8513A

P50

Q36937170-788EFAF4-1401-4767-B311-219B0B15EC28

Q36937170-8C337754-1F95-4FE8-94A4-423742A431EC

P577

Q36937170-0798020D-DF49-4860-A7E8-C16D52297A02

P698

Q36937170-02437B11-8617-437B-9834-B8035854B85E

P932

Q36937170-6684798A-8D76-4B2B-A10E-86019E769109

P356

0008-5472.CAN-12-1335

P1433

Cancer Research

P1476

Distinct patterns of dysregula ...... static prostate cancer tumors.

@en

P2093

Bin He

http://www.w3.org/2001/XMLSchema#string

Charles L Sawyers

http://www.w3.org/2001/XMLSchema#string

Chris Sander

http://www.w3.org/2001/XMLSchema#string

Clifford C Sung

http://www.w3.org/2001/XMLSchema#string

Daniel C Danila

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Martin Fleisher

http://www.w3.org/2001/XMLSchema#string

Nicholas Mitsiades

http://www.w3.org/2001/XMLSchema#string

Vijay Kumar Eedunuri

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Abiraterone and increased survival in metastatic prostate cancer

Integrative genomic profiling of human prostate cancer

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

ARN-509: a novel antiandrogen for prostate cancer treatment

P304

6142-6152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-12-1335

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Nikolaus Schultz

P577

2012-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22971343

http://www.w3.org/2001/XMLSchema#string

P932

3685485

http://www.w3.org/2001/XMLSchema#string